19 January 2016

Novozymes Breaks Off Biopharma into Independent Company Named Albumedix

Today, Novozymes announced it has separated its biopharma activities into an independent company called Albumedix. The new company will be fully owned by Novozymes. Albumedix will continue to develop its market leading position within recombinant albumin-based products and technologies. Albumin is a naturally occurring protein that can be found in human blood. Albumedix will be led by CEO Peter Rosholm, who previously headed Novozymes’ Biopharma business. The leadership team will report to an independent board consisting of three directors from the pharmaceutical industry and two representatives from Novozymes. Source: Biospace 19/1/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).